OVERCOMING BIOLOGICAL BARRIERS TO DRUG DELIVERY

The Mitchell Lab is based in the Department of Bioengineering at the University of Pennsylvania. Our research lies at the interface of biomaterials science, drug delivery, and cellular and molecular bioengineering to fundamentally understand and therapeutically target biological barriers. We apply our research findings and the technologies developed to a range of human health applications, including cancer metastasis, immunotherapy, genome editing, cardiovascular disease, and regenerative medicine. Current research projects include: synthesis of novel biomaterials and nanoparticles for the delivery of nucleic acids (siRNA, miRNA, mRNA, CRISPR-Cas9) for cancer therapy; engineering of immune cells for immunotherapy and vaccines; investigating the influence of biomaterial chemical structure on in vivo transport to target cells and tissues using high-throughput screening platforms; and novel drug delivery technologies for tissue engineering and regenerative medicine.

RECENT NEWS

April 2020 – Congratulations to BE PhD students Rebecca Haley and Sarah Shepherd for being awarded NSF GRFP Fellowships. Their fellowships and research projects are featured by Penn Bioengineering.

March 2020 – Congratulations to BE Postdoctoral Fellow Rachel Riley for accepting an Assistant Professor of Biomedical Engineering position at Rowan University. Rachel’s new position is featured by Penn Bioengineering.

January 2020 – Maggie’s paper on lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering is published in Nano Letters and is featured by Penn Today and Penn Engineering.

August 2019 – Mike receives the T. Nagai Award from Professor Kazunori Kataoka at the Controlled Release Society Annual Meeting in Valencia, Spain. Photo courtesy of Professor Nicholas Peppas.